Clínica Médica
Guia prático | Tratamento de sintomas em pacientes com cirrose.
21 Mar, 2022 | 16:13hSymptom Management in Patients with Cirrhosis: a Practical Guide – Current Treatment Options in Gastroenterology (gratuito por tempo limitado)
Comentário da autora no Twitter (fio – clique para saber mais)
Published today! @rrosenblattmd and I discuss treatment considerations in patients with cirrhosis, including ascites, encephalopathy, pruritus, muscle cramping, pain, depression/anxiety, fatigue, and appetite⬇️ #livertwitter #cirrhosis #ESLD https://t.co/qjPCX5YPP7
— Aly J. Kaplan, MD (@aly_kaplanMD) March 17, 2022
Estudo de coorte | Características e desfechos do infarto agudo do miocárdio tipo 2.
21 Mar, 2022 | 16:05hCharacteristics and Outcomes of Type 2 Myocardial Infarction – JAMA Cardiology (link para o resumo – $ para o texto completo)
Comentários:
Type 2 MI Not Uncommon in the Emergency Department – TCTMD
Type 2 Myocardial Infarction: Clinical Characteristics and Outcomes – American College of Cardiology
Comentário no Twitter
Among patients presenting with acute chest discomfort to the emergency department, tachyarrhythmias and hypertension are responsible for more than two thirds of type 2 myocardial infarction and result in a lower mortality compared to other triggers. https://t.co/ODMCmOjeQO
— JAMA Cardiology (@JAMACardio) March 10, 2022
Estudo randomizado | Contezolida oral vs. linezolida em adultos com infecções cutâneas e de partes moles complicadas.
21 Mar, 2022 | 15:58hA Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections – Journal of Antimicrobial Therapy (link para o resumo – $ para o texto completo)
Comentário no Twitter
Phase III efficacy & safety of oral contezolid Vs linezolid in adults with c.SSTIs
📌Non inferior
📌Interestingly:Contezolid demonstrated significant lower incidence thrombocytopenia (0% Wow vs 2.3%) & leucopenia (0.3% vs 3.4%) than linezolid
📌QIDP https://t.co/wSvxUInnkZ— Antibiotic Steward Bassam Ghanem (@ABsteward) March 11, 2022
Decisão do consenso de especialistas da ACC de 2022 sobre sequelas cardiovasculares de COVID-19 em adultos: miocardite e outros envolvimentos miocárdicos, sequelas pós-agudas da infecção pelo SARS-CoV-2 e volta aos esportes.
17 Mar, 2022 | 13:25hComentários:
ACC Issues Clinical Guidance on CV Consequences of COVID-19 – American College of Cardiology
ACC Releases Guidance on CV Issues With COVID-19 – TCTMD
Pontos principais: 2022 ACC Decision Pathway on Cardiovascular Sequelae of COVID-19
Conteúdos relacionados:
Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.
The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.
COVID-19 infections increase risk of heart conditions up to a year later, study finds.
Comentário no Twitter (fio – clique para saber mais)
Access the full ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-acute Sequelae of SARS-CoV-2 Infection, and Return to Play: https://t.co/ph75qZxfpT #JACC @JACCJournals #CardioTwitter (8/8) pic.twitter.com/mpYJic6gem
— American College of Cardiology (@ACCinTouch) March 16, 2022
Revisão do estado de arte | Avanços recentes no diagnóstico e tratamento da cefaleia em salvas.
17 Mar, 2022 | 13:23hRecent advances in the diagnosis and management of cluster headache – The BMJ
Evidências Cochrane | Tratamento para COVID-19 moderada a grave.
17 Mar, 2022 | 13:22hTreatments for moderate to severe COVID-19: Cochrane evidence – Evidently Cochrane
Evidências Cochrane | Tratamento para COVID-19 leve.
17 Mar, 2022 | 13:20hTreatments for mild COVID-19: Cochrane evidence – Cochrane Library
Entre profissionais da área da saúde, a efetividade da 4ª dose de vacina contra infecção pela variante Ômicron do SARS-CoV-2 foi de 30% para a Pfizer–BioNTech e 11% para a Moderna.
17 Mar, 2022 | 13:19hEfficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron – New England Journal of Medicine
Conteúdo relacionado: [Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.
Efetividade das vacinas Sputnik V, AstraZeneca e Sinopharm para o risco de infecção e morte por COVID-19 em idosos com mais de 60 anos na Argentina.
17 Mar, 2022 | 13:17hComentário: Evaluating COVID-19 vaccines in the real world – The Lancet
[Comunicado de imprensa – ainda não publicado] Estudo EMPA-KIDNEY de fase III sobre empaglifozina será interompido precocemente em razão de evidência da eficácia em pessoas com doença renal crônica.
17 Mar, 2022 | 13:16h
Comentário no Twitter
Details of the design & pt characteristics now published:
6609 people from 8 countries
(UK, Germany, Italy, USA, Canada, China, Malaysia, Japan)
Mean age 64 years
1/3 female
1/2 diabetes; 1/2 without
3/4 eGFR <45 mL/min/1.73 m2.
1/2 uACR <300 mg/g https://t.co/jOD8kyp3i4 pic.twitter.com/YYpGPJDnV9— Martin Landray (@MartinLandray) March 16, 2022